PeptiDream Inc. (4587) Stock Price

Peptidream operates a drug discovery and development business utilizing PDPS, its proprietary drug discovery platform system. Through this business, the company leverages core drug discovery platform technologies centered on PDPS to conduct collaborative research and development, technology licensing, and strategic partnerships to expand its own pipeline.

PDR Pharma, a 100% subsidiary of Peptidream, operates a radiopharmaceutical business. This division engages in research, development, manufacturing, and sales of diagnostic radiopharmaceuticals used to image lesions such as cancer and abnormal brain accumulation, as well as therapeutic radiopharmaceuticals primarily for oncology.

PDR Pharma's products sold in Japan include sodium iodide capsules, Liathyr MIBG-I131 injection, and Zevalin Indium (111In) injection kits. These products are used for diagnosis and treatment of hyperthyroidism and cancer.

Additionally, PDR Pharma provides radiopharmaceuticals for diagnosing kidney and lung diseases, including Techne DMSA kits and Techne MAA kits. These products contribute to improved diagnostic accuracy in clinical settings.

Through both drug discovery and radiopharmaceutical businesses, Peptidream and PDR Pharma are engaged in research, development, manufacturing, and sales of pharmaceuticals, aiming for innovation in the healthcare sector.

PeptideDream aims to create next-generation pharmaceuticals by advancing innovative drug research and development based on its proprietary drug discovery platform, PDPS. The company leverages PDR Pharma's expertise in radiopharmaceuticals to contribute to human health and medical advancement.

PeptideDream operates across two strategic business areas: radiopharmaceuticals (RI) and non-radiopharmaceuticals (Non-RI). In the RI segment, the company develops innovative radiotherapeutics and diagnostic agents using technology that selectively delivers radionuclides to cancer cells. In the Non-RI segment, the company focuses on peptide drug discovery and peptide-drug conjugate development centered on PDPS.

The company targets revenue of 49,000 million yen, core operating profit of 21,700 million yen, and a core operating profit margin of 44.3% by 2025. These goals aim to improve profitability and achieve sustainable growth.

In the radiopharmaceutical segment, key strategic pillars include maximizing value from existing products, expanding into the central nervous system market, and developing new radiotherapeutics. The company prioritizes growth in PET diagnostic agents for Alzheimer's disease, aiming to provide valuable information to healthcare professionals.

In the Non-RI segment, the company advances peptide drug and conjugate discovery based on PDPS while strengthening partnerships. This approach supports programs from early research through commercialization, driving future revenue expansion.

PeptideDream leverages synergies with PDR Pharma to pursue innovation in healthcare through both drug discovery and radiopharmaceutical businesses. The company aims to achieve sustainable and robust growth while contributing to medical progress.